<DOC>
	<DOCNO>NCT02455804</DOCNO>
	<brief_summary>This prospective , post-marketing , non-randomized , multi-center , single-arm clinical study conduct 15 site United States ( US ) . All subject treat NIRxcell Stent System follow 30 day , 9 month 1 , 2 3 year post-index stenting procedure . An unscheduled follow may conduct clinically warrant .</brief_summary>
	<brief_title>NIRTRAKS Post-Market Study ( NIRTRAKS )</brief_title>
	<detailed_description>The main objective study collect analyze additional information safety effectiveness NIRxcell Stent System treatment de novo stenotic lesion native coronary artery US population . The primary endpoint rate target vessel failure ( TVF ) 3 year treatment NIRxcell Stent System . This rate compare performance goal derive meta-analysis coronary stenting bare metal stent ( BMS ) .</detailed_description>
	<criteria>General 1 . Subject ≥18 year old . 2 . Subject eligible percutaneous coronary intervention ( PCI ) . 3 . Subject eligible dual antiplatelet therapy ( DAPT ) aspirin plus either clopidogrel , prasugrel ticagrelor minimum 1 month . 4 . Subject understands nature procedure provide write informed consent prior catheterization procedure . 5 . Subject willing comply specify followup evaluation contact telephone . 6 . Subject acceptable candidate coronary artery bypass graft ( CABG ) surgery . 7 . Subject stable angina pectoris ( Canadian Cardiovascular Society Classification [ CCSC ] 1 , 2 , 3 4 ) unstable angina pectoris ( Braunwald Class 13 , BC ) positive functional ischemia study ( e.g . exercise tolerance test [ ETT ] , singlephoton emission computerize tomography [ SPECT ] , stress echocardiography cardiac computerize tomography [ CT ] ) . 8 . Female subject child bear potential must negative pregnancy test within 7 day prior enrollment study . Angiographic Inclusion Criteria 1 . Subject indicated elective stenting single stenotic lesion native coronary artery . 2 . Reference vessel ≥2.5 mm ≤4.0 mm diameter visual estimate . 3 . Target lesion ≤30 mm length visual estimate ( intention cover whole lesion 1 stent adequate length ) . 4 . Target lesion stenosis ≥50 % &lt; 100 % visual estimate . General Exclusion Criteria 1 . Subject currently enrol another investigational device drug trial complete primary endpoint clinically interfere current study endpoint . 2 . Subject enrol another stent trial within 2 year prior index procedure . 3 . Any planned elective surgery percutaneous intervention within 9 month post procedure . 4 . A previous coronary interventional procedure kind within 30 day prior procedure . 5 . The subject require staged procedure either target vessel nontarget vessel within 9 month postprocedure . 6 . The target lesion require treatment device percutaneous transluminal coronary angioplasty ( PTCA ) prior stent placement ( , limit , directional coronary atherectomy , excimer laser , rotational atherectomy , etc. ) . 7 . Previous drugeluting stent ( DES ) deployment anywhere target vessel . 8 . Any previous DES deployment within past 12 month . 9 . Any previous stent placement within 15 mm proximal distal target lesion . 10 . Comorbid condition ( ) could limit subject 's ability participate trial comply followup requirement , impact scientific integrity trial . 11 . Concurrent medical condition life expectancy &lt; 3 year . 12 . Documented leave ventricular ejection fraction ( LVEF ) &lt; 25 % recent evaluation . 13 . Evidence acute MI within 72 hour intend index procedure . 14 . History cerebrovascular accident transient ischemic attack within 6 month prior index procedure . 15 . Leukopenia ( leukocytes &lt; 3.5 x 109/liter ) . 16 . Neutropenia ( absolute neutrophil count &lt; 1,000/mm3 ) ≤ within 7 day prior enrollment . 17 . Thrombocytopenia ( platelet &lt; 100,000/mm3 ) preprocedure ( within 7 day prior enrollment ) . 18 . Active peptic ulcer active gastrointestinal ( GI ) bleeding . 19 . Subjects ineligible ≥1 month DAPT bleed diathesis reason . 20 . Known hypersensitivity contraindication aspirin , thienopyridine , heparin bivalirudin , cobalt , nickel , L605 cobalt chromium alloy sensitivity contrast medium adequately premedicated . 21 . Serum creatinine level &gt; 2.5 mg/dL within 7 day prior index procedure . 22 . Subject previously enrol PIONIR Study NIRTRAKS PostMarket Study . Angiographic Exclusion Criteria 1 . Unprotected leave main coronary artery disease ( obstruction &gt; 50 % leave main coronary artery protect ≥1 nonobstructed bypass graft leave anterior descend [ LAD ] leave circumflex [ LCX ] artery branch thereof ) . 2 . Target vessel exhibit multiple lesion &gt; 60 % diameter stenosis outside range 5 mm proximal distal target lesion base visual estimate online quantitative coronary angiography ( QCA ) . 3 . Target lesion exhibit intraluminal thrombus ( occupy &gt; 50 % true lumen diameter ) time prior start intervention . 4 . Lesion location aortoostial within 5 mm origin LAD LCX . 5 . Target lesion side branch &gt; 2.0 mm diameter . 6 . Target lesion involve bifurcation ( either stenosis main vessel major branch stenosis major branch ) . 7 . Target lesion severe calcification . 8 . Target vessel exhibit excessive tortuosity may impede stent delivery deployment target lesion . 9 . Target lesion locate native vessel distal anastomosis saphenous vein graft left/right internal mammary artery ( LIMA/RIMA ) bypass .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>